Upcoming ipo: molbio diagnostics files draft papers with SEBI to raise funds via public edition

Goa-based Molbio Diagnostics Limited, backed by Themesk and Motilal Oswal Private Equity, submitted draft documents at the Securities and Exchange Board of India (Sebi) to obtain capital through an initial public offer (IPO). According to the draft Red Herring Prospectus (DRHP), the IPO will include a new issue of stock shares worth up to £ 200 and an offer-for-sell (OFS) of up to 1.25 crore shares by existing investors. The company intends to award £ 99.3 crore from the proceeds to establish infrastructure for a new research and development center, a center of excellence and associated office facilities. In addition, £ 73.5 crore will be used to buy plants and machinery for its manufacturing units in Goa and Visakhapatnam, with the rest earmarked for general corporate purposes. Founded in 2000, Molbio Diagnostics specializes in molecular diagnostics for more than 30 diseases, including tuberculosis, Covid-19, HIV, HPV, and Hepatitis B&C. The flagship ‘Truenat’ platform-a batteries-adjusted, portable PCR device can deliver in more than 100 countries. The company operates five manufacturing facilities: Two in Goa, one in Visakhapatnam, and two in Bengaluru, and manufactures devices, test sets and radiological equipment via its subsidiary, Prognosys Medical Systems. On March 31, 2025, Molbio’s annual production capacity stood on 3600 devices and 3.9 crore truenat test kits. For FY25, this reported an income of £ 1,020 crore, which was a year-by-year growth of almost 22%, and a profit after tax of £ 138.5 crore. Kotak Mahindra Capital, IIFL Capital Services, Jefferies India, and Motilal Oswal Investment Advisors are the general managers running through the book. (With input from PTI) Disclaimer: This story is for educational purposes only. The views and recommendations above are those of individual analysts or brokerage companies, not coin. We advise investors to check with certified experts before making investment decisions.